Welcome To PI3K Pathways Summit

 The PI3K Pathways Summit will assess the challenges and opportunities in the PI3K field right now and examine cutting-edge scientific advances which aim to improve the potency, tolerability and safety profiles of drugs targeting this pathway for use in cancer treatment.

Attend this virtual meeting to discuss lessons learnt from preclinical and translation data, explore innovative strategies for targeting the pathway to address key challenges and gain an understanding of the implications of PI3K genomic alterations in oncology and other disease areas.  

Whether you’re part of a PI3K-focused biotech, a pharmaceutical organization assessing this exciting field, or an academic researcher with breakthrough findings, join the PI3K Pathways Summit as we explore the advances in PI3K field and gain networking invaluable opportunities to network with like-minded peers from industry and academia who are striving to understand the mechanistic, preclinical and clinical implications of PI3K in oncology and beyond.

5 Reasons To Not Miss Out:


Discover unpublished preclinical data from studies of novel PI3K targeted therapies, explore key clinical case studies of approved PI3K inhibitors and reflect on lessons learnt from both academia and industry to inform your future research decisions.


Define the desirable attributes of next generation of PI3K inhibitors and explore strategies for developing these drugs.


Navigate PI3K inhibitor adverse side-effects to reduce on-target toxicity and increase tolerability.


Discuss the importance of PI3K inhibitor combination strategies to enhance efficacy, reduce dosage requirements, produce synergistic effects, and mitigate against resistance.


Debate the benefits and challenges of PI3K isoform specific vs pan PI3K inhibitors in the treatment of both hematological and solid tumors and understand the optimal isoform profile for each.